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PURPOSE. Endothelial nitric oxide synthase (eNOS)-derived nitric oxide (NO) has important
vasoprotective functions that are compromised in the vasodegenerative phase of retinopathy
of prematurity, owing to hyperoxia-induced depletion of the essential NOS cofactor BH4.
Because modulating eNOS function can be beneficial or detrimental, our aim was to investigate
the effect of BH4 supplementation on eNOS function and vascular regression in hyperoxia.
METHODS. Endothelial-specific eNOS-green fluorescent protein (GFP) overexpressing mice at
postnatal day 7 (P7) were exposed to hyperoxia for 48 hours in the presence or absence of
supplemental BH4, achieved by administration of sepiapterin, a stable BH4 precursor. Tissue
was collected either for retinal flat mounts that were stained with lectin to determine the
extent of vessel coverage or for analysis of BH4 by high-performance liquid chromatography,
nitrotyrosine (NT) marker by Western blotting, VEGF expression by ELISA, and NOS activity
by arginine-to-citrulline conversion. Primary retinal microvascular endothelial cells (RMEC)
were similarly treated, and hyperoxia-induced damage was determined.
RESULTS. Sepiapterin effectively enhanced BH4 levels in hyperoxia-exposed retinas and brains,
elevated NOS activity, and reduced NT-modified protein, leading to reversal of the
exacerbated vasoregression observed in the presence of eNOS overexpression. In RMECs,
hyperoxia-mediated depletion of BH4 dysregulated the redox balance by reducing nitrite and
elevating superoxide and impaired proliferative ability. BH4 supplementation restored normal
RMEC proliferation in vitro and also in vivo, providing a mechanistic link with the enhanced
vascular coverage in eNOS-GFP retinas.
CONCLUSIONS. These results demonstrate that BH4 supplementation corrects hyperoxia-
induced RMEC dysfunction and preserves vascular integrity by enhancing eNOS function.
Keywords: endothelial nitric oxide synthase, retinal vasculature, retinopathy of prematurity
Retinopathy of prematurity (ROP) is a sight-threateningcomplication of premature birth that is compounded by
the therapeutic hyperoxia that is essential for the survival of
premature infants.1,2 Development of the inner retinal circulation
occurs in the third trimester of pregnancy; therefore, when
infants are born prematurely, this normal retinal vascular
development is stunted. The hyperoxic environment causes
further regression of the pre-existing immature vessels (phase 1).
Thus, when oxygen is removed, the resulting vascular insuffi-
ciency leads to irreversible ischemia-induced tissue damage and
hypoxia-induced intravitreal neovascularization (NV; phase 2),
which, if left untreated, leads to vision loss.1,2 Importantly, there
is a strong correlation between the extent of avascularity in phase
1 and severity of NV in phase 2, in which infants born very
prematurely have larger areas of ischemia and more severe retinal
neovascularization.3,4 This suggests that treatments that could
preserve endothelial cell (EC) integrity during hyperoxia and
support normal vascular development could reduce the need for
treatments such as pan retinal laser photocoagulation and
intravitreal injections of anti-VEGF agents, which focus on late
disease and carry significant risk of serious complications.5,6
Mechanistically, a significant amount of research indicates a
central role for oxidative stress in the initial cell injury in ROP and
subsequent vasoregression.7–10 In this regard, we and other
investigators have previously shown that the nitric oxide (NO)-
producing enzyme endothelial NO synthase (eNOS) plays an
important role in such oxidative injury to the immature retinal
vasculature.7,10,11 More specifically, using a loss of function
transgenic model, Brookes et al.7 showed that reducing
peroxynitrite levels by eNOS depletion in eNOS knockout
animals reduced capillary dropout and enhanced vascular
coverage following hyperoxia, demonstrating a role for eNOS-
derived peroxynitrite in promoting vascular regression. At the
other extreme, using a gain of function transgenic model with
augmented endothelial-specific eNOS expression (eNOS-green
fluorescent protein [GFP] transgenic animals), we showed that
eNOS is dysfunctional in hyperoxia and acts as a source of the
oxygen free radical superoxide (O2
) instead of its normal
vasoprotective product, NO, dysregulating the cellular redox
balance and exacerbating retinal vascular regression.10,12–14 In a
separate study, we showed that hyperoxia depletes levels of the
NOS cofactor tetrahydrobiopterin (BH4) in the neonatal retina,
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resulting in eNOS uncoupling and a shift from NO to O2
.10,15
This eNOS dysfunction was reversed by supplementing ex vivo
tissue homogenates with BH4.10 Together, these findings indicate
that, in hyperoxia, there is a nonstoichiometric relationship
between active eNOS and BH4 for optimal NO production and
suggests that correction of the discrepancy could translate to
improved eNOS-mediated vascular preservation in vivo.16,17
Manipulating eNOS activity can have either beneficial or
detrimental consequences, especially in a pro-oxidant environ-
ment such as hyperoxia. In such situations, the presence of
reactive oxygen species (ROS) would negate the positive impact
of NO and even exacerbate vascular damage through the
reaction of ROS and NO, leading to higher levels of relatively
long-lived peroxynitrite levels and exacerbating outcomes for the
vasculature. Thus, here our aim was to determine whether
supplementing BH4 levels in vivo could reverse the impaired
eNOS function and protect the retina from hyperoxic insult. Our
working hypothesis was that improving BH4 levels to compen-
sate for its oxidative loss in elevated oxygen would diminish
hyperoxia-induced vascular regression by normalizing the
cellular redox balance. In order to manipulate the relative levels
of eNOS and BH4, we used neonatal animals overexpressing
eNOS specifically in the vascular endothelium and treatment
with sepiapterin to increase BH4.
MATERIALS AND METHODS
eNOS-GFP Animals and Hyperoxia Treatment
Animals overexpressing eNOS-GFP (a kind gift from Professor
Rini de Crom, Department of Cell Biology and Genetics,
Erasmus University Medical Centre Rotterdam, Rotterdam, The
Netherlands) on a C57/BL6 background were used. These
animals carry the full-length human genomic DNA sequence,
including the endogenous eNOS promoter, fused in frame with
an enhanced GFP (eGFP) reporter sequence, allowing expres-
sion of a functional eNOS-GFP fusion protein, as described
previously.10,18 Heterozygote eNOS-GFP-positive animals and
their wild-type (WT) homozygous littermate controls were
used throughout. All animal studies were performed under a
project license issued by the UK Home Office (Animals
Scientific Procedures Act 1986), approved by the local animal
care ethics committee, and conducted in accordance with the
ARVO statement for the use of Animals in Ophthalmic and
Vision Research. The in vivo protocol was based on the early
hyperoxia-induced vaso-obliterative (VOB) stage of the murine
oxygen-induced retinopathy (OIR) model.19 According to this
protocol, neonatal mice and their nursing dams are exposed to
75% oxygen between postnatal day 7 (P7) and P9 to P12, a
time frame when the primary inner plexus of the retinal
vasculature is complete but still vulnerable to hyperoxic
damage. The resulting EC dysfunction leads to regression of
pre-existing retinal vessels, evident as large areas of avascular
central retina.7,10,15 Thus, for all in vivo studies, WT and eNOS-
GFP transgenic animals were exposed to 75% oxygen from P7
to P9 before tissues were collected for processing.
Retinal Flat Mount Processing and Vascular
Phenotype
Paraformaldehyde (PFA)-fixed eyes were flat mounted, and
blood vessels were labeled with biotinylated isolectin (20 lg/
mL; Sigma-Aldrich, Gillingham, UK), followed by streptavidin
Alexa Fluor-405 or 568 conjugate (Life Technologies Ltd., Paisley,
UK), as described previously.10,15 Lectin-stained flat-mounted
retinas were imaged using a fluorescence microscopy (Eclipse
E400 model; Nikon Corporation, Kingston upon Thames, UK),
and vascular coverage was measured using NIS Elements BR
software (Nikon Corporation).
Biopterin Analysis by HPLC
Tissue BH4 and BH2 (an oxidation product of BH4 that
competitively inhibits the catalysis of NO conversion) were
measured, along with standards, by high performance liquid
chromatography (HPLC) with fluorescence detection after
iodine oxidation in acidic or alkaline conditions as described
previously.15,20,21 BH4 concentrations, expressed as nanograms
per milligram of protein, were calculated by subtracting BH2
plus oxidized biopterin from total biopterin.
In Vivo Supplementation Protocol
Supplementation with BH4 was achieved by the addition of
sepiapterin, a stable synthetic pterin converted intracellularly
to BH4 through the pterin salvage pathway, as described
previously.22–25 At P7, mice were assigned to the control or
treatment group. Wild-type and eNOS-GFP transgenic animals
were supplemented with BH4 and subjected to 75% oxygen
from postnatal days 7 to 9. Treatment was administered by
intraperitoneal injection, 10 mg/kg sepiapterin dissolved in
dimethyl sulfoxide (DMSO), based on the manufacturer’s
recommendations, with control animals receiving an equiva-
lent amount of DMSO diluted in sterile saline solution (vehicle
control [VC] of 3.5% [v/v] or 0.35 lL/g DMSO). This
sepiapterin concentration was based on evidence from other
studies that this dose is well tolerated and results in elevation
of tissue BH4 level that produce physiologically measurable
effects.23–25 Following 48 hours exposure to 75% oxygen, eyes
were collected and fixed for lectin staining, or retinal and brain
tissue were collected and immediately snap frozen on dry ice
and stored at 808C for later analysis.
NOS Activity Assay
Nitric oxide in tissue samples was measured by NOS activity by
the conversion of radiolabeled arginine-to-citrulline, using a
modified NOS activity assay in the absence of additional assay
BH4 and in the presence of an arginase inhibitor, as described
previously (Cayman Chemical, Ann Arbor, MI, USA).15,26 For
each sample, background was determined by incubation in the
presence of N-Nitro-L-arginine (L-NNA) and subtracted from
the total counts. A portion of the sample was used for Western
blotting.
Western Blotting
Nitrotyrosine (NT) assay Western blotting was conducted as
previously described.15,26 Equivalent amounts of protein
sample, typically 30 lg, were separated on a 9% SDS-
polyacrylamide gel, transferred to polyvinylidene fluoride
membrane (Millipore, Watford, UK) and immunostained with
anti-eNOS, iNOS, nNOS (BD Biosciences, Oxford, UK), or
monoclonal anti-NT (Cayman Chemicals) primary antibodies,
followed by the appropriate horseradish peroxidase-conjugat-
ed secondary antibody (Insight Biotechnology Ltd., London,
UK). b-Actin mouse monoclonal antibody (Sigma-Aldrich) was
used to verify equivalency of loading.
VEGF ELISA
Retinas were pooled and homogenized in phosphate-buffered
saline (PBS) containing protease inhibitors, and VEGF levels
were determined by ELISA (R&D Systems, Minneapolis, MN,
USA), as described previously.15
BH4-Mediated Vascular Preservation in Neonatal Hyperoxia IOVS j January 2017 j Vol. 58 j No. 1 j 231
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935965/ on 02/24/2017
Dopamine ELISA
Pooled retinal samples were homogenized in lysis buffer (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, and 1% nonionic nondenaturing
detergent [IGEPAL CA-630]) containing 10 mM ascorbic acid and
0.1 mM EDTA and assayed for dopamine, using an ELISA kit
(catalog number BA E-5300; Labor Diagnostika Nord, Nordhorn,
Germany), as described previously.15
Primary Retinal Microvascular Endothelial Cell
(RMEC) Culture and Measurement of Cellular BH4
Levels
Primary retinal microvascular ECs (RMEC) were isolated and
cultured from bovine eyes, as described previously, and
routinely grown on gelatin-coated tissue plates (1%; Sigma-
Aldrich).27 Hyperoxia treatment was performed by maintaining
cells in 75% oxygen/5% CO2, using a gas controller (Proox
model C21 and C-Chamber incubator insert; BioSpherix,
Lacona, NY, USA).
In Vitro BH4 Supplementation
RMEC (80,000 cells per well) were seeded onto 1% gelatin-
coated 6-well plates and, after 24 hours, when cells were
approximately 50% confluent, were incubated in growth
medium containing vehicle control (1:10,000 dilution of
DMSO), 0.1lM sepiapterin (dissolved in DMSO; Sigma-Aldrich),
or 1 lM sepiapterin and placed under hyperoxic or normoxic
conditions for 24 hours. For BH4 and BH2 measurements, cells
were collected by trypsinization, and the resulting cell pellet
was snap frozen on dry ice and stored at 808C until analysis.
Briefly, cell pellets were homogenized in cold extraction buffer
(50 mM Tris-HCl, pH 7.4, 1 mM dithiothreitol [DTT], 1 mM
ethylenediaminetetraacetic acid [EDTA]; all Sigma-Aldrich) and
centrifuged at 14,000 rpm for 15 minutes at 48C. BH4 levels
were determined by HPLC with fluorescence detection after
iodine oxidation under acidic or alkaline conditions, as
described above and previously.15 Parallel plates were used to
measure superoxide detection by dihyroethidium (DHE) or
proliferation by 5-ethynyl-20-deoxyuridine (EdU).
Nitrite Measurements
Nitric oxide was measured by accumulation of the stable by-
product nitrite by using the Griess assay.27 Briefly, RMEC,
seeded onto 24-well plates, were treated with sepiapterin in
phenol red-free Dulbecco’s modified Eagle medium (Life
Technologies Ltd.) in the presence or absence of the NOS
inhibitor N-Nitro-L-arginine methyl ester (L-NAME, 1 mM;
Sigma-Aldrich) and exposed to normoxic and hyperoxic
conditions for 24 hours. Following treatment, medium was
removed and centrifuged before addition of Griess reagent, and
sample absorbance was detected at 540 nm (FLUOstar Omega;
BMG Labtech, Aylesbury, UK).
EdU Assay
Proliferation was assessed in RMEC by EdU incorporation,
using the Click-iT EdU imaging kit (Life Technologies). RMEC
(80,000 cells per well) were seeded onto gelatin-coated glass
cover slips and allowed to attach overnight. Cells were then
treated with sepiapterin or VC and exposed to 75% oxygen
(with normoxic controls) in the presence of EdU (10 lM).
Following incubation, cells were fixed with 3% PFA for 15 min
at room temperature, rinsed twice with blocking buffer (3%
BSA; Sigma-Aldrich) in PBS, and then permeabilized with 0.5%
Triton X-100 in PBS for 20 minutes. Cells were washed twice
more and stained with Alexa-Fluor-555 fluorescent nuclear dye
marker (Life Technologies) and Hoechst 33342 dye (Life
Technologies) before mounting with Vectashield (Vector
Laboratories Ltd., Peterborough, UK). Nonoverlapping images
were collected for each treatment (4 images each from
triplicate wells) by using inverted confocal laser scanning
microscopy (TE2000-U; Nikon Corp.), and the percentage of
EdU-positive cells, as the percentage of the total cell number,
was determined by Hoechst 33342 dye staining, using EZ
Freeviewer version 3.9 software (Nikon Corp.).
DHE For Analysis of Superoxide Production
In situ free radical production was assayed using the oxidative
fluorescent dye DHE, in the presence and absence of the
inhibitors PEG-SOD and L-NAME.27 Cells were treated as
described above, rinsed in phenol red-free Dulbecco’s modified
Eagle medium, incubated with 5 lM DHE (Life Technologies)
diluted in the same medium, and exposed to normoxic and
hyperoxic conditions for 24 hours. Cells were also reacted
with DHE in the presence of L-NAME (1 mM) and PEG-SOD
(100 U/mL; Sigma-Aldrich). Three images were collected per
well from 6 wells per treatment, using inverted confocal laser
scanning microscopy, with identical acquisition settings for
comparison of intensities.
BrdU Labeling of Hyperoxia-Treated P9 Pups and
Branch Point Analysis
For in vivo analysis of proliferation, mice were injected
intraperitoneally with 300 lg of 50-bromo-20 deoxyuridine
(BrdU; Life Technologies), 3 hours before being euthanized on
P9 following supplementation. Eyes were fixed in 4% PFA-PBS
for 30 min at room temperature and washed with PBS before
being incubated with formamide-SSC (NaCl and sodium citrate)
solution for 1 hour at 658C. Retinas were then incubated in 6 N
HCl solution for 30 min at 378C and then neutralized by
washing with 0.1 M Tris-HCl (pH 8.0). Specimens were treated
with blocking buffer, then incubated overnight at 48C with anti-
BrdU antibody (Dako, Ely, UK), and washed again. Secondary
goat anti-mouse antibody (Alexa Fluor 546; Life Technologies)
was added before mounting. Images were obtained at 4003
magnification. The number of BrdU-positive nuclei within the
lectin-stained vascular area was quantified and expressed per
retinal quadrant. Branching was also determined from the same
sections as previously described.10,15
Statistical Analysis
Statistical analysis was performed using Prism version 5.03
software (GraphPad Software, La Jolla, CA, USA) by indepen-
dent Student’s t-test to determine differences between the two
groups (*P < 0.05; **P < 0.01; ***P < 0.001). When compari-
sons between more than two groups were performed, 1-way
ANOVA with Bonferroni’s multiple comparison test was used
to determine statistical significance. Data are means 6 SEM
from 3 to 6 individual litters. For in vitro studies, all experi-
ments were performed using at least 3 independent isolations
and are the results of 3 to 4 independent experiments, unless
otherwise indicated.
RESULTS
Effect of Hyperoxia on Vascular Regression and
Retinal BH4 Levels
Hyperoxia-induced vascular regression was observable as a
vessel-free zone in the central retina in neonatal pups at P9
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after 48 hours’ hyperoxia (Fig. 1A). Previously, we showed that
exposure to 5 days of hyperoxia in eNOS-GFP mice exacerbat-
ed vaso-obliteration compared to their WT counterparts.10
Here, using the shorter exposure of 48 hours to elevated
oxygen, we showed that vascular regression at P9 was
comparable to that previously seen at P12 (Figs. 1A, 1B).
Importantly, the exacerbated regression previously reported in
the eNOS-GFP group was also evident at P9 (28.4% in WT
mice) and 33.2% (eNOS-GFP mice). Comparison of BH4 levels
between P9 room air controlled and hyperoxia-treated P9
retinas showed a significant decrease (almost 30% reduction)
in BH4 levels (Fig. 1C).
Efficacy of Sepiapterin to Elevate Retinal BH4
Levels and Effect of Supplementation on
Hyperoxia Between P7 and P9
Next, we investigated whether supplementing retinal BH4
levels could reverse the hyperoxia-mediated defect in BH4
levels and prevent vascular regression. BH4 is easily oxidized,
therefore, BH4 supplementation was achieved by addition of
sepiapterin, which has previously been shown to raise tissue
BH4 levels more efficiently than BH4 in mice.23 We first
confirmed the ability of sepiapterin to increase BH4 in the
retina and demonstrated that increased levels were detectable
48 hours after injection in brain and retinal tissue samples
following hyperoxia (Fig. 2A, Supplementary Fig. S1).
Sepiapterin supplementation of mice at P7 and subsequent
hyperoxic exposure for 48 hours resulted in a significant
elevation of BH4 levels in retinal (Fig. 2A) and brain
(Supplementary Fig. S1) tissue: BH4 increased by 67% in
WT and 55% in eNOS-GFP mice in retinal samples, demon-
strating no effect of genotype. BH2 is an oxidation product of
BH4 that competes with BH4 and reduces the ability of eNOS
to produce NO; accordingly, studies have suggested that the
BH2:BH4 ratio is more predictive of eNOS dysfunction than
the absolute concentration of BH4. Here, in contrast to the
BH4 levels, which were similar across genotypes, there was a
measurable difference in BH2 (Fig. 2B) in the eNOS-GFP
group compared to that in WT VC-treated controls; this
FIGURE 1. Hyperoxia causes vascular regression and depletes BH4 in vivo. Hyperoxia exposure of mouse pups from P7 to P9 results in a marked
vascular regression and depleted retinal BH4 levels. (A) Representative images of room air controlled and hyperoxia-exposed animals. Hyperoxia-
induced vascular regression in the central retina (yellow) is significantly enhanced in eNOS-GFP animals compared to their WT litter mate controls.
(B) Avascular or VO area is expressed as a percentage of total retinal area. (C) Hyperoxia exposure of mouse pups results in a marked reduction in
retinal BH4 levels measured by HPLC. *P < 0.05, **P < 0.01.
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resulted in a decrease in the level of BH4 relative to that of
BH2, suggesting some oxidation (Fig. 2C) in the presence of
eNOS overexpression. Importantly, this was normalized by
sepiapterin, in correspondence with the reversal by sepiap-
terin of the hyperoxia-associated decrease in NOS activity
(Fig. 2E). Hyperoxia reduced NOS activity by 61% and 47% in
WT and eNOS-GFP, respectively, compared to room air-treated
controls. In eNOS-GFP animals, the hyperoxic reduction in
NOS activity was paralleled by an increase in NT immunore-
activity (Fig. 2D), demonstrating increased peroxynitrite
formation compared to that in WT mice. These findings,
together with the higher BH2 in the eNOS-GFP group,
indicated higher generation of peroxynitrite and peroxyni-
trite-mediated BH4 oxidation. Sepiapterin treatment reduced
this retinal NT immunoreactivity (Fig. 2D) and reversed the
hyperoxia-mediated defect in NOS activity (Fig. 2E) in the
eNOS-GFP group, confirming a BH4-dependent impairment in
NOS function in hyperoxia. Expression of eNOS-GFP fusion
protein or endogenous eNOS was unaffected by treatment
(Fig. 2D). Together, these findings are indicative of improved
NO availability and decreased oxidative free radical produc-
tion following supplementation. In contrast to the augmented
eNOS group, in the WT group the effect of sepiapterin on the
level of NT was minimal. Notably, however, this correlated
with raised VC-treated BH4 levels compared to the control
group shown in Figure 1; 0.75 ng/mg protein in the hyperoxia
treated group (Fig. 1) was raised to 1.7 ng/mg protein in the
VC group (Fig. 2), suggesting that vehicle alone had some
antioxidant effects. This effect was also evident in the lower
NT immunoreactivity of the WT VC group; supplementation
had no further measurable effect on NT levels.
BH4, in addition to being a cofactor for eNOS, is a cofactor
for the other NOS isoforms, inducible and neuronal NOS, and is
also a cofactor for the aromatic hydroxylases. Here, retinal
dopamine levels were quantified following sepiapterin supple-
mentation in room air-control animals and showed an elevation
in dopamine levels that was similar for both genotypes
(Supplementary Fig. S2A). In contrast, in the same experimen-
tal groups, the BH4-mediated rise in NOS activity was much
more pronounced in the eNOS-GFP group than in the WTs
FIGURE 2. Sepiapterin supplementation increases retinal BH4 levels and improves NOS enzymatic activity, which correlates with a reduction in
oxidative stress. eNOS-GFP and WT littermates were injected with VC or sepiapterin at P7 before being exposed to hyperoxia for 48 hours. (A–C)
Sepiapterin supplementation caused a significant increase in retinal BH4 level in both WT and eNOS-GFP mice. Histogram shows representative data
from 1 of 3 experiments. (D) NT protein level was measured by Western blot analysis as an indicator of retinal oxidative stress. Following treatment
with BH4, there is a significant reduction in the level of NT-modified protein in eNOS-GFP mice. Total eNOS protein in the same sample assayed for
NT shows the eNOS protein level in VC is equivalent to that in the sepiapterin group. (E) Analysis of NOS activity showed a significant increase in
NOS activity in supplemented mice compared to that in controls. *P < 0.05, **P < 0.01, ***P < 0.001.
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(Supplementary Fig. S2B). Together, this demonstrated that NO
production and not dopamine was differentially enhanced by
the presence of additional eNOS. Thus, any differences in
vascular responsiveness between the groups (WT versus eNOS-
GFP) is due to endothelial eNOS overexpression. Expression
levels of eNOS, nNOS, and iNOS were also determined in the
same samples (Supplementary Fig. S2C). ENOS expression was
elevated in the eNOS-GFP groups as expected, iNOS was not
present, and nNOS showed a small increase in expression in
both the WT and eNOS-GFP groups after sepiapterin supple-
mentation. Because the expression levels were similar between
the two genotypes, any differences in effect of genotype on
total NOS activity were considered likely to be mediated by the
presence of the eNOS-GFP transgene.
Effect of BH4 Supplementation on Hyperoxia-
Induced Vascular Regression in the Presence of
eNOS Overexpression
In the WT group, BH4 supplementation produced a marginal
decrease in vascular closure compared to VC (Fig. 3A, 3B) from
25.4% avascular area in the VC to 23.6% in the sepiapterin
group. Notably, compared to the uninjected controls shown in
Figure 1, this value was more pronounced (28.4% control [C]
[Fig. 1] to 23.6% sepiapterin-treated [Fig. 3]), indicating that, in
agreement with the VC-induced increase in BH4 levels, there
was evidence that the vehicle had a small effect on vascular
preservation and enhanced vascular coverage. Importantly, in
the eNOS-GFP group, BH4 supplementation had a more
pronounced impact on the vascular free areas (Fig. 3A, 3B)
and reversed the exaggerated response seen in the absence of
adequate BH4 levels (34% VC decreased to 23% sepiapterin).
VEGF levels were unchanged in all treatments (Fig. 3C).
Effect of Hyperoxia on BH4 Levels and eNOS
Function in RMEC
Next we wanted to investigate the mechanism of the BH4-
mediated improvement in vascular preservation in hyperoxia,
specifically in RMECs. In cells subject to high oxygen
conditions, biopterin levels demonstrated a significant hyper-
oxia-induced depletion (almost 2-fold) of BH4 (Fig. 4A). BH2
FIGURE 3. Sepiapterin administration reduces vascular regression following hyperoxia exposure in eNOS-GFP mice. (A) Vaso-obliteration following
hyperoxia exposure in eNOS-GFP mice is reduced following sepiapterin administration. Mice were injected at P7 prior to being placed into a
hyperoxic chamber. (B) Avascular area or VO area, shown as a percentage of total retinal area, in eNOS-GFP mice was significantly higher than that
in WT mice. Supplementation with sepiapterin caused a significant decrease in VO area in eNOS-GFP mice. (C) VEGF was measured by ELISA in
pooled retinal sample lysate following sepiapterin supplementation. Scale bars: 500 lm; n ¼ 3 litters per group. **P < 0.01.
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was slightly elevated in hyperoxia compared to that in
normoxia (Fig. 4B), resulting in a decrease in the BH4:BH2
ratio (Fig. 4C), suggesting that in hyperoxia, a small percentage
of BH4 was oxidized to BH2. These findings correlated with a
3-fold decrease in nitrite levels (Fig. 4D). Hyperoxia had a
marginal effect on apoptotic cell death (data not shown);
however, the effect was slight compared to the effect on
proliferative potential of the cells; EdU positivity was reduced
from 42.1% 6 2.5%, expressed as [%EdU-positive/total cell
number/well] in normoxia to 22.9% 6 1.3% in hyperoxia (Fig.
4E, 4F).
Effect of Sepiapterin Supplementation on
Hyperoxia-Mediated RMEC Dysfunction
In vitro, using sepiapterin concentrations previously shown to
cause a beneficial BH4- dependent increase in NO levels in EC,
we showed an elevation of BH4 levels in normoxia (Fig. 5A).22
In hyperoxic samples, there was a similar, albeit smaller,
increase. The levels of BH2 (Fig. 5B) were increased in a similar
manner, indicating some oxidation of BH4 that was consistent
in both normoxia and hyperoxia. Calculated relative to each
other, there was a reduction in the BH4:BH2 ratio in hyperoxia
only at the highest concentration (Fig. 5C). Overall, however,
there was a total increase in BH4, demonstrating that the
sepiapterin had compensated for the hyperoxia-induced BH4
defect. Notably, compared to cells treated in the absence of
vehicle (Fig. 4A), the degree of hyperoxia-induced reduction in
BH4 shown in Figure 5A was not as marked, indicting some
effect of the vehicle alone.
Next, the consequences of BH4 supplementation on
function were determined by nitrite and in situ free radical
production and showed that sepiapterin reversed the hyper-
oxia-induced decrease in nitrite, in line with the improvements
in BH4 levels (Fig. 5B, Supplementary Fig. S3). Measurement of
superoxide production by DHE fluorescence showed a
hyperoxia-induced increase which was markedly inhibited by
sepiapterin, especially at the highest concentration (Fig. 5C).
DHE fluorescence was inhibited by SOD and L-NAME,
indicating NOS was one of the sources of superoxide
(Supplementary Fig. S4). In normoxia, the sepiapterin had a
small effect on proliferation, an effect likely to be due to the
high baseline proliferative rate in these cells (Fig. 5D, 5E). In
contrast, sepiapterin had a marked restorative effect on
proliferation and reversed the hyperoxia-induced proliferative
impairment.
Effect of BH4 on Retinal EC Proliferation In Vivo
The proliferation and branching of vascular cells (Supplemen-
tary Fig. S5) at the vascular-avascular interface was quantified
following hyperoxia by BrdU incorporation. In line with the
improvement in vascular coverage in the supplemented group
in the presence of augmented eNOS, there was a marked
increase (54%) in eNOS-GFP retinas (Fig. 6). Notably, the
largest difference in proliferation in the presence of additional
BH4 was observed close to the interface between the vascular
and avascular retina. Together, this demonstrated that the BH4-
dependent improvement in eNOS activity had a positive effect
on proliferation in vivo. Vascular branching was increased in
both groups (WT and eNOS-GFP), suggesting some effect of
BH4 on the WT group that was not observed in the
determination of vascular coverage shown in Figure 3.
FIGURE 4. In vitro, hyperoxia depletes BH4 levels, reduces nitrite formation, and impairs the proliferative ability of RMEC. (A) RMECs were cultured
under normoxic and hyperoxic conditions for 24 hours and samples were collected and biopterin levels were analyzed by HPLC. BH4 was
significantly reduced by hyperoxia exposure, and this was reflected in an increase in (oxidized) BH2. (D) Measurement of nitrite from cells cultured
in hyperoxia indicates that there is a significant reduction in nitrite production compared to that in normoxia. Scale bars: 200 lm. (E) Assessment of
proliferation by EDU staining indicates that hyperoxia reduces proliferation in RMECs exposed to 75% oxygen. (F) Representative images. *P < 0.05,
**P < 0.01, ***P < 0.001.
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DISCUSSION
In ROP, the stunting of normal inner retinal vascular
development has sight-threatening consequences for infants
born very prematurely. Current treatments for ROP focus on
late disease and are not always effective. An ideal treatment
strategy would not only target the initial vasodegenerative
stage to preserve EC integrity and prevent capillary regression
but also enable continued vascular development during
hyperoxia and prevent progression to the sight-threatening
neovascular stage of disease. Using loss- and gain-of-function
mutants, we and others previously showed that dysfunctional
eNOS and eNOS-derived peroxynitrite play an important role
in driving vacsular regression in hyperoxia.7,10
Our group has also shown that hyperoxia has significant
consequences for BH4 bioavailability and eNOS function in the
neonatal retina, suggesting limiting BH4 levels as one
mechanism responsible for the impaired eNOS function.10,15
eNOS has important prorepair functions in normal vascular
development and ischemia. Therefore, here our aim was to
FIGURE 5. Sepiapterin supplementation improves BH4 levels in hyperoxia, increases production of nitrite, and enhances RMEC proliferation. (A)
HPLC analysis of biopterin levels in proliferating RMECs treated with sepiapterin under normoxic and hyperoxic conditions shows that hyperoxia
exposure results in reduced BH4, which can be improved by supplementation with sepiapterin. (B) Nitrite measured using the Griess assay
following 24 hours hyperoxia exposure. Under hyperoxic conditions, nitrite production in all treatment groups was significantly decreased
compared to that under normoxia and increased by sepiapterin. (C) Measurement of superoxide production by DHE indicates that there is a
significant increase in superoxide production in hyperoxia, which is reduced by sepiapterin under normoxic and hyperoxic conditions. (D)
Immunolocalization of EDU, a marker of proliferation, is shown. Hyperoxia reduces proliferation in RMECs. This can be corrected by addition of
sepiapterin to cells (E). Data were derived from n ¼ 3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001. Scale bars: 200 lm.
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investigate whether supplementing in vivo with BH4 would
reverse the hyperoxia-induced eNOS defect and exacerbated
capillary regression and be therapeutically beneficial.
In this study, we report several novel findings and show that
the hyperoxia-induced vascular damage observed in the
presence of eNOS overexpression is reversed by BH4
supplementation acting, in part, via a reversal in hyperoxia-
induced EC proliferative impairment. First, in a transgenic
model of endothelium-specific eNOS overexpression, we
showed that hyperoxia decreases BH4 levels in retinas of
animals. This finding is consistent with our previous study
using isolated retinal homogenates where we showed that
there was a mismatch between the level of total eNOS
expression and enzymatic activity with a concomitant increase
in ROS production.10 This defect in enzyme function was
partly corrected by the addition of BH4 to the homogenate,
allowing us to infer that the amount of BH4 was insufficient to
supply the demands of the additional eNOS and responsible for
the eNOS dysfunction during hyperoxia. Here, in the current
study, by specifically measuring BH4 after hyperoxia in the
same strain, we showed further evidence for this hypothesis.
Moreover, this was further corroborated by the finding that in
vivo BH4 supplementation led to a significant improvement in
NOS activity, NO bioavailability, and a decrease in hyperoxia-
induced oxidative stress and reversed the exaggerated vascular
regression observed in this model, consistent with a normal-
ization of eNOS to NO output. Together, this provides evidence
that normalizing the cellular redox state has a beneficial
outcome in hyperoxia.
With regard to magnitude of effect, there was still some
evidence that the redox balance could be improved further.
For example, in the hyperoxic eNOS retinas, the BH4:BH2
FIGURE 6. eNOS functional normalization is associated with enhanced EC proliferation during hyperoxia exposure. (A) The proliferation of vascular
cells in the central retinal region at the vascular-avascular interface was quantified following hyperoxia by BrdU incorporation. (B) Sepiapterin
supplementation caused a significant increase in the number of cells showing BrdU positivity. (C) Low-power image of retinal flat mount indicating
area of sampling ([A] yellow). Original magnification is 43. (D) Retinal vascular branching was also increased following supplementation. Scale
bars: 100 lm; n¼ 3 litters per group. *P < 0.05, **P < 0.01, *** P < 0.001.
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ratios were slightly lower than those in WT mice following
sepiapterin supplementation, suggesting some peroxynitrite-
induced oxidation of BH4 to BH2. This was also evident in the
NOS activity assay, whereby sepiapterin increased NOS activity
to similar levels in both the WT and eNOS-GFP groups.
Although it is possible that this might have been due to
autoinhibition of eNOS, taken together with the BH4:BH2
ratios, it is also likely to be caused by a higher residual
proportion of dysfunctional eNOS in the augmented eNOS
group.28 The latter would suggest that the amount of
bioavailable BH4 is still not optimal or the involvement of an
alternative BH4-independent mechanism of eNOS uncoupling,
such as oxidative-stress induced glutathionylation of eNOS.29
Together, this suggests further avenues for improving vascular
outcomes during hyperoxia to maximize the effect of eNOS
functional preservation.
Vascular growth in the retina is driven and guided by
hypoxia-induced VEGF released from retinal neural cells or
astrocytes. In hyperoxia, this relationship is disturbed, and
both a decrease in the prosurvival cues of VEGF and a
reduction in VEGFR2/Akt signaling are proposed to lead to
apoptotic EC death, initiating vascular regression.2,11 Signifi-
cantly, here we show that the effects observed were
independent of VEGF levels, which were unaffected by BH4
supplementation, suggesting an EC cell autonomous role for
eNOS and BH4 in improved vascular coverage. Thus, second,
because ROP primarily affects the vasculature, we showed that
hyperoxia specifically depleted BH4 levels in isolated EC with
adverse consequences on nitrite production and proliferative
potential. Third, we showed that this hyperoxia-induced defect
was reversible by increasing BH4 levels, which increased
nitrite and importantly also decreased hyperoxia-induced ROS
production, indicative of improved NOS function. This positive
effect on the cellular redox balance partly reversed the
hyperoxia-induced proliferative defect in RMEC, confirming a
BH4-dependent mechanism involved in promoting EC growth
that is compromised by hyperoxia. Other groups have focused
on studying the effect of hyperoxia on apoptosis.9,11 Here, we
decided to focus on studying the effects of hyperoxia on
proliferation, as these effects were much greater than those
measured for apoptosis. Thus, fourth, we also showed that, in
common with the in vitro results, BH4 supplementation
improved the proliferative rate of retinal EC in the eNOS-GFP
group in vivo, demonstrating that the vasoprotection afforded
by BH4 promoted continued proliferation during hyperoxia.
Taken together, our results here show that a BH4-dependent
increase in EC proliferation in eNOS-GFP animals aids in
maintaining vascular coverage in hyperoxia. This is in line with
previous studies showing a role for eNOS-derived NO in
regulating the cell cycle; indeed, the critical role for eNOS in
this pathway is evidenced by studies in eNOS/ mice, which
have a significant disruption in the expression of cell cycle
genes during collateral vascular development following ische-
mia.30 Diabetic animals also show a NOS-dependent impair-
ment in EC proliferative ability that is reversed by replenishing
BH4 levels, restoring their ability to synthesize NO and
proliferate more efficiently.31,32 Importantly, our studies
suggest that this important function of eNOS-derived NO
during development is similarly inhibited by hyperoxia and
that the enhanced vascular coverage in the BH4-treated eNOS
group is due in part to continued proliferation in hyperoxia.
Interestingly, the differences in proliferative response and
vascular branching were most pronounced close to the
interface between the vascular and avascular retina, suggesting
that these cells were undergoing continued growth when
eNOS function was optimal.
With regard to choice of modulating agent, because BH4 is
labile, it would be difficult to administer directly to the retinal
circulation. Importantly, sepiapterin, as well as being more
stable, had the advantage of being able to cross the blood brain
barrier in addition to having good tissue retention proper-
ties.20,23 Indeed, here we show that sepiapterin is efficiently
delivered to the retina and is functionally translated into
increased BH4 and a significant improvement in NOS activity.
In order to improve the stability of BH4, we used DMSO as
vehicle, which interestingly alone showed evidence of having a
vasoprotective effect. In this study, there was clear evidence
that the vehicle was modulating BH4 levels, suggestive of an
antioxidant effect. This was more obvious in the WT group,
evident as elevated retinal BH4 levels, reduced NT, and
improved vascular area compared to uninjected controls.
DMSO has previously been reported to have antioxidant and
immunosuppressive effects, to be inhibitory to EC prolifera-
tion, and to be antithrombotic.33–35 The results of this study
suggest that these effects are mediated in part by altering BH4
levels, resulting in a vasoprotective outcome in the retina.
Interestingly, despite evidence of a marked BH4-mediated
increase in nitric oxide and NOS activity, BH4 showed only
marginal benefit on vascular branching and coverage in WT
retinas but had a pronounced positive impact in the eNOS-GFP
retinas. Thus, an intriguing aspect of our findings was that,
although there was a marked increase in NOS activity following
BH4 supplementation, this increase did not yield a better
outcome in terms of capillary cover. In contrast, in isolated EC,
BH4 had a much more marked effect on hyperoxia-induced EC
damage. Together, this suggests a retinal specific or non-EC-
derived effect limiting the beneficial outcome of sepiapterin
supplementation on vascular coverage. One particular strength
of our study was the use of the EC-specific eNOS-GFP animals
to manipulate the relative levels of eNOS and BH4 specifically
in the endothelium. Taking the in vivo and in vitro results
together, our results suggest that a nonvascular/non-EC-derived
factor is having an effect on vascular growth. In addition to
eNOS, BH4 is also a cofactor for nNOS and the aromatic
hydroxylases. Tyrosine hydroxylase is particularly prevalent in
early development and is strongly expressed in retinal neural
cells; therefore, sepiapterin had the potential to alter the
activity of tyrosine hydroxylase.36 Indeed, we have previously
shown that lower retinal BH4 levels in GTP-cyclohydrolase
(GTPCH)-deficient animals correlated with reduced dopamine
levels.15 Here, sepiapterin did indeed elevate dopamine levels
in the neonatal retina to a similar degree in both the WT and
eNOS-GFP groups. As a neural tissue, the parenchymal cells of
the retina have a significant influence on vascular develop-
ment: highest during the first week of postnatal week
following birth.37 During this timeframe, the cross-talk
between the tyrosine hydroxylase-positive dopaminergic ama-
crine cells and the vasculature would be particularly influen-
tial. Because dopamine inhibits EC proliferation and is
antiangiogenic, BH4-dependent mechanisms would also have
a consequence on this pathway.38 Indeed, we found previously
that GTPCH-deficient hph-1 mice display a decrease in NOS
and dopamine levels, which enhanced VEGF levels during
development.15 With regards to nNOS, we did not observe any
evidence of compensatory changes in expression across
genotypes as described in eNOS/ animals.39 However it is
likely that sepiapterin increased the activity of nNOS similarly
in both groups that was evident as an additional increase in
total NOS activity above that produced by eNOS. Importantly,
there is increasing evidence of neural cell involvement in
vascular development; therefore, taking the paradoxical
elevation in NOS activity in the WT along with the small effect
on vascular coverage, it is possible that neuronal or perivas-
cular nNOS-derived NO is limiting vascular growth, as it does in
the brain during a similar developmental window to that
investigated here.39,40 In the current study, supplemental
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retinal BH4 levels only had a marginal effect on vascular
regression in the WT group. It is therefore possible that the
increased dopamine or nNOS activity following sepiapterin
supplementation negated the impact of enhanced endogenous
eNOS activity in the WT group. The eNOS-GFP group however,
allowed us to directly compare the effect of eNOS when BH4
levels were limiting, as was the case during hyperoxia and
when supplementary BH4 was sufficient to drive eNOS activity
and endothelial proliferation. This is an important mechanism
to define, as putative therapies that reduce overall cellular
oxidative stress, for example by inhibiting EC-derived eNOS,
would also inhibit its prosurvival and reparative functions.
Taken together, our study demonstrates that, in the
presence of additional eNOS, the levels of BH4 are insufficient
to enable the eNOS-GFP animals to, first, overcome the
hyperoxia-induced detriment of BH4 deficiency and, second,
to capitalize on the proangiogenic benefits of more functional
eNOS activity and that, importantly, supplementation with BH4
can reverse this defect. Previous studies have shown the
importance of nitro-oxidative stress as a driver of the VOB
phase of OIR and have also shown that peroxynitrite
scavengers decrease vaso-obliteration.7,9 Here we show, in
addition to the decrease in oxidative stress, the benefit of
modulating EC-specific BH4 levels to promote eNOS function
and facilitate its reparative roles.
With regards to a therapy to prevent ROP, timing of
treatment is critical. For example, in line with the differential
effects of VEGF in phase 1 (protective) and NV promoting in
phase 2, hyperoxia-mediated impairment of VEGFR2 signaling
is beneficial in the ischemic phase of OIR, when VEGF
activation is maximal.2,11,41 Like VEGF in phase 2, prolonged
eNOS activation, especially during ischemia, is likely to
increase both normal and NV growth; therefore, titrating the
benefits of BH4 will be important considerations for future
therapies. Importantly, intervening in phase 1 would have the
potential to preserve vascular integrity and prevent progres-
sion to the sight-threatening NV stage. In this regard, newly
approved stabilized BH4, already in clinical use for GTPCH-
deficient dystonia, could be used to increase BH4 levels
globally.42 Our results, however, argue for an endothelial-
specific enhancement of BH4. Therefore, treatment strategies
would be best used if targeted to the endothelium or in
combination with other agents known to protect the retinal
circulation in early ROP. This combined approach could, for
example, include erythropoietin. Previously shown to be
protective against hyperoxia-induced vessel loss in OIR,
erythropoietin has also been shown to increase BH4 bioavail-
ability and protect against oxidative stress induced by eNOS
uncoupling in the cerebral microvasculature, suggesting a BH4-
eNOS–mediated mechanism for its beneficial effects on the
retina.43,44 Several other agents, notably ascorbic acid and
folate, are also known to alter EC-BH4 levels and could
therefore be administered safely to premature infants to
prevent ROP. In addition to ROP, eNOS function also plays an
essential role in diabetes. For example, eNOS knockout animals
have a greater range of retinal vascular complications.45 Thus,
strategies that preserve the prosurvival functions of eNOS
would also be beneficial for the prevention of diabetic
retinopathy.
In summary, our findings show an important role for BH4
and eNOS in hyperoxia-induced proliferative impairment and
vasoretardation in the retina and the positive impact that
improving eNOS has on vascular integrity in hyperoxia in the
neonate. We also show the validity of using BH4 supplemen-
tation to harness the prorepair functions of eNOS in the
endothelium and protect against hyperoxic insult. Importantly,
this knowledge will aid the development of new strategies to
preserve vascular integrity and facilitate normal vascular
development in the neonate.
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